1. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment.
- Author
-
Asano T, Hirano S, Nakamura T, Okamura K, Tsuchikawa T, Noji T, Nakanishi Y, Tanaka K, and Shichinohe T
- Subjects
- Academic Medical Centers, Adult, Aged, Aged, 80 and over, Chemoradiotherapy mortality, Cohort Studies, Conservative Treatment methods, Feasibility Studies, Female, Follow-Up Studies, Humans, Japan, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Invasiveness pathology, Neoplasm Recurrence, Local physiopathology, Neoplasm Staging, Pancreatectomy mortality, Pancreatic Neoplasms diagnostic imaging, Pancreatic Neoplasms therapy, Retreatment, Retrospective Studies, Risk Assessment, Statistics, Nonparametric, Survival Analysis, Treatment Outcome, Chemoradiotherapy methods, Neoplasm Recurrence, Local mortality, Pancreatectomy methods, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery
- Abstract
Background: Conversion surgery (CS) is expected as a new therapeutic strategy for patients with unresectable pancreatic cancer (UR-PC). We analyzed outcomes of CS for patients with UR-PC and evaluated the survival benefit of CS., Methods: Thirty-four patients diagnosed with UR-PC according to the National Comprehensive Cancer Network guideline underwent CS in our hospital. Resectability was considered by multimodal images in patients who underwent nonsurgical treatment (NST) for more than 6 months. CS was performed only in patients who were judged to be able to undergo R0 resection., Results: Twenty-six patients had locally advanced PC, and eight had distant metastases. The median duration of NST was 9 (range 5-44) months. R0 resection was achieved in 30 patients (88.2%). Six patients (17.6%) showed Evans grade ≥III. Three- and 5-year overall survival (OS) rates from initial treatment were 74% and 56.9%, respectively, with median survival time (MST) of 5.3 years. The actual 5-year OS rate in 19 patients was 47.4% with an MST of 4.0 years. Patients with Evans grade ≥III had a better prognosis than those with Evans grade
- Published
- 2018
- Full Text
- View/download PDF